Results 21 to 30 of about 26,548 (293)

Eplerenone–A novel Mineralocorticoid receptor antagonist for the clinical application

Environmental Disease, 2022
Aldosterone is produced from the zona glomerulosa of the adrenal cortex in the adrenal gland, which is main mineralocorticoid hormone. Upon binding the mineralocorticoid receptor, it regulates sodium and potassium absorption, secretion, and retention ...
Nan-Nan Wu, Yuan-Yuan Zhang, Dong Zhao
doaj   +1 more source

Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. [PDF]

Eur J Heart Fail, 2022
Yang M, Butt JH, Kondo T, Jering KS, Docherty KF, Jhund PS, de Boer RA, Claggett BL, Desai AS, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Langkilde AM, Martinez FA, Petersson M, Shah SJ, Vaduganathan M, Wilderäng U, Solomon SD, McMurray JJV.   +20 more
europepmc   +2 more sources

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources

Mineralocorticoid receptor antagonist use following heart failure hospitalization

ESC Heart Failure, 2020
Aims Patients hospitalized for heart failure (HF) are at increased risk for events post‐discharge. Mineralocorticoid receptor antagonists (MRAs) improve the clinical course of patients with HF with reduced ejection fraction.
Jason M. Duran, Shady Gad, Alison Brann, Barry Greenberg   +3 more
doaj   +1 more source

The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome [PDF]

, 2019
When hypertension, a pathology that is frequently found in the general population, presents in a young patient, secondary causes such as Cushing's syndrome (CS), a rare disease characterized by long-term elevated cortisol levels, should be considered ...
Barbot, Mattia, Ceccato, Filippo, Scaroni, Carla   +2 more
core   +1 more source

Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]

, 2017
No abstract ...
Aspirin Myocardial Infarction Study Research Group, Baigent, Baigent, Bonaca, Chin, Cleland, Cleland, Cleland, Cleland, Cleland, Cleland, Gelder, Homma, Lewis, Massie, Meune, Michel, Pitt, Pitt, Silva, Solomon, Tweeddale, Zannad, Zannad   +23 more
core   +1 more source

Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockade.

PLoS ONE, 2014
Aldosterone administration in rats results in several cardiac alterations. Previous studies have demonstrated that proanthocyanidins, phenolic bioactive compounds, have cardioprotective effects.
Beatriz Martín-Fernández, Natalia de las Heras, María Valero-Muñoz, Sandra Ballesteros, Yi-Zhou Yao, Peter G Stanton, Peter J Fuller, Vicente Lahera   +7 more
doaj   +1 more source

Mineralocorticoid receptor blockade during a rat's first violent encounter inhibits its subsequent propensity for violence. [PDF]

, 2013
In individuals naive to serious conflict in an unfamiliar environment, violence has long-lasting effects on subsequent aggressive behavior. This effect of the stressful experience of a first violent conflict occurs in victims as well as offenders.
Haller, József, Kloet, E. R., Kruk, M. R., Meelis, W.   +3 more
core   +1 more source

Drug treatment of hypertension: focus on vascular health [PDF]

, 2016
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C., Lang, Ninian N., Touyz, Rhian M.   +2 more
core   +1 more source

Mineralocorticoid receptor antagonists in cardiovascular translational biology

Cardiovascular Endocrinology & Metabolism, 2023
This review examines the role of mineralocorticoid receptor antagonists (MRAs) in cardiovascular biology and the molecular mechanisms involved in mineralocorticoid receptor antagonism. The data discussed suggest that MRAs can play an important role in decreasing the impact of inflammation and fibrosis on cardiorenal outcomes.
Chilton, Robert J., Silva-Cardoso, José
openaire   +2 more sources